Choong Ang Vaccine Laboratory
KOSDAQ:072020
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (6.4), the stock would be worth ₩10 366.56 (7% upside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6 | ₩9 710 |
0%
|
| 3-Year Average | 6.4 | ₩10 366.56 |
+7%
|
| 5-Year Average | 9.4 | ₩15 352.85 |
+58%
|
| Industry Average | 16.8 | ₩27 428.25 |
+182%
|
| Country Average | 8.5 | ₩13 913.87 |
+43%
|
Forward EV/EBITDA
Today’s price vs future ebitda
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
C
|
Choong Ang Vaccine Laboratory
KOSDAQ:072020
|
90.9B KRW | 6 | 13.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
869.1B USD | 27.8 | 41.1 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
555.5B USD | 16.6 | 25.9 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 11.7 | 19.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
231.9B GBP | 16.2 | 29.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
226.8B CHF | 12.4 | 20 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 9.6 | 15.3 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 386.8 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 8 | 10.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.5B USD | 7.7 | 20 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
119B USD | 7.1 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 5.3 |
| Median | 8.5 |
| 70th Percentile | 15.6 |
| Max | 24 013.5 |
Other Multiples
Choong Ang Vaccine Laboratory
Glance View
Choong Ang Vaccine Laboratory Co., Ltd. engages in the manufacture and sale of animal medicines and products. The company is headquartered in Daejeon, Daejeon. The company went IPO on 2003-10-31. The firm provides veterinary vaccines for fowl, dogs, pigs, cattle, rabbits, cats, fishes and others under the brand name SuiShot, PoulShot, Canishot, BoviShot, FeliShot, RabbiShot and AquaShot. The firm also provides diagnosis services, and distributes other veterinary drugs, such as antibiotics, anthelmintics, disinfectants and feed additives. The firm distributes its products within domestic market and to overseas markets.
